SCHEMBL6108317

SCHEMBL6108317

N#Cc1ccc2[nH]cc(CCCl)c2c1

nearest known ligand 0.73

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 11/20 0.64
DRD2 P14416 3/20 0.51
DRD4 P21917 3/20 0.51
DRD3 P35462 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6879916 0.91 SLC6A4 (0.69) SLC6A4
SCHEMBL30468389 0.91 SLC6A4 (0.69) SLC6A4
SCHEMBL29499049 0.90 SLC6A4 (0.67) SLC6A4
SCHEMBL3082624 0.90 SLC6A4 (0.67) SLC6A4
SCHEMBL18011078 0.88 SLC6A4 (0.66) SLC6A4
SCHEMBL25244606 0.84 SLC6A4 (0.64) SLC6A4DRD2DRD4DRD3
SCHEMBL8136598 0.84 SLC6A4 (0.64) SLC6A4DRD2DRD4DRD3
SCHEMBL2531600 0.84 SLC6A4 (0.64) SLC6A4DRD3
SCHEMBL12881233 0.84 SLC6A4 (0.68) SLC6A4DRD2DRD4DRD3
SCHEMBL27402888 0.84 SLC6A4 (0.64) SLC6A4DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122191-A1 N-(indolethyl-)cycloamine compounds MERCK PATENT GMBH (DE) 2006-06-08 US claimed
EP-1572646-A1 N-(INDOLETHYL-)CACLOAMINE COMPOUNDS MERCK PATENT GmbH (DE) 2005-09-14 EP claimed
WO-2004054972-A1 N-(INDOLETHYL-)CACLOAMINE COMPOUNDS MERCK PATENT GMBH (DE) 2004-07-01 WO claimed
US-20060122191-A1 N-(indolethyl-)cycloamine compounds MERCK PATENT GMBH (DE) 2006-06-08 US disclosed
EP-1572646-A1 N-(INDOLETHYL-)CACLOAMINE COMPOUNDS MERCK PATENT GmbH (DE) 2005-09-14 EP disclosed
WO-2004054972-A1 N-(INDOLETHYL-)CACLOAMINE COMPOUNDS MERCK PATENT GMBH (DE) 2004-07-01 WO disclosed
CN-1056610-C Piperidines and piperazines MERCK PATENT GMBH (DE) 2000-09-20 CN disclosed
EP-0648767-B1 Piperdine and piperazine derivatives which affect the C.N.S. MERCK PATENT GMBH (DE) 1997-05-28 EP disclosed
US-5532241-A Piperidines and piperazines MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1996-07-02 US disclosed
CN-1106811-A Piperidines and piperazines MERCK PATENG GES MIT BESCHRAEN (DE) 1995-08-16 CN disclosed
EP-0648767-A1 Piperdine and piperazine derivatives which affect the C.N.S. MERCK PATENT GmbH (DE) 1995-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122191-A1 N-(indolethyl-)cycloamine compounds HTR1A, HTR2A, HTR5A SLC6A4 93/4885DRD2 59/4885DRD4 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.